ERBB2 and breast carcinoma: Moreover, both Her-2 immunohistochemical (IHC) (3+) and Her-2 (2+)/FISH (+) patients are classified as Her-2 positive breast cancer; it is yet to be determined whether different levels of Her-2 protein expression will yield the same prognosis under the same dual-target neoadjuvant therapy regimen.